Alaunos Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
501 E LAS OLAS BLVD, FORT LAUDERDALE, FL, 33301
Mailing Address
501 E LAS OLAS BLVD, FORT LAUDERDALE, FL, 33301
Phone
(346) 355-4099
Fiscal Year End
1231
EIN
841475642
Financial Overview
FY2025
$6.31M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 5, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | January 15, 2026 | View on SEC |
| 4 Insider stock transaction report | January 15, 2026 | View on SEC |
| 4 Insider stock transaction report | January 15, 2026 | View on SEC |
| 8-K Current report of material events | January 8, 2026 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | December 5, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Pivoted business model to focus exclusively on ALN1003, an oral pill candidate for obesity and metabolic disorders.
- Achieved proof-of-concept data in mouse studies showing weight loss and improved liver health.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.